“Across all systemic medication exposures, heparin use was associated with lower erythropoiesis stimulating agent (ESA) dose, higher hemoglobin levels, and lower monthly intravenous (IV) iron dose ; lower rates of clotting during treatment and hospitalization for GI bleeding; and similar rates of peri-treatment bleeding.”